Harding Loevner’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $578K | Sell |
1,163
-312,383
| -100% | -$138M | 0.01% | 75 |
|
|
2026
Q1 | $140M | Sell |
313,546
-78,319
| -20% | -$36.5M | 1.44% | 22 |
|
|
2025
Q4 | $178M | Sell |
391,865
-64,123
| -14% | -$27.6M | 1.56% | 20 |
|
|
2025
Q3 | $179M | Sell |
455,988
-255,623
| -36% | -$107M | 1.31% | 26 |
|
|
2025
Q2 | $317M | Buy |
711,611
+13,152
| +2% | +$6.06M | 2.13% | 16 |
|
|
2025
Q1 | $339M | Sell |
698,459
-125,168
| -15% | -$58.3M | 2.59% | 13 |
|
|
2024
Q4 | $332M | Sell |
823,627
-328,998
| -29% | -$153M | 2.24% | 14 |
|
|
2024
Q3 | $536M | Sell |
1,152,625
-31,783
| -3% | -$15.3M | 3.09% | 10 |
|
|
2024
Q2 | $555M | Sell |
1,184,408
-38,630
| -3% | -$16.8M | 3.06% | 10 |
|
|
2024
Q1 | $511M | Sell |
1,223,038
-98,191
| -7% | -$41.5M | 3.16% | 8 |
|
|
2023
Q4 | $539M | Sell |
1,321,229
-25,522
| -2% | -$9.43M | 3.02% | 7 |
|
|
2023
Q3 | $468M | Sell |
1,346,751
-191,519
| -12% | -$67M | 3.09% | 7 |
|
|
2023
Q2 | $541M | Sell |
1,538,270
-288,354
| -16% | -$97.2M | 3.16% | 7 |
|
|
2023
Q1 | $576M | Sell |
1,826,624
-13,897
| -0.8% | -$4.17M | 3.28% | 7 |
|
|
2022
Q4 | $532M | Buy |
1,840,521
+200,704
| +12% | +$61.2M | 3.06% | 8 |
|
|
2022
Q3 | $475M | Sell |
1,639,817
-93,874
| -5% | -$27M | 3.11% | 7 |
|
|
2022
Q2 | $489M | Sell |
1,733,691
-35,585
| -2% | -$9.52M | 3.01% | 8 |
|
|
2022
Q1 | $417M | Sell |
1,769,276
-112,595
| -6% | -$26.7M | 2.3% | 13 |
|
|
2021
Q4 | $413M | Sell |
1,881,871
-29,232
| -2% | -$5.68M | 1.58% | 26 |
|
|
2021
Q3 | $347M | Sell |
1,911,103
-87,975
| -4% | -$17.2M | 1.38% | 28 |
|
|
2021
Q2 | $403M | Buy |
1,999,078
+15,989
| +0.8% | +$3.34M | 1.52% | 24 |
|
|
2021
Q1 | $426M | Sell |
1,983,089
-60,006
| -3% | -$13.2M | 1.67% | 22 |
|
|
2020
Q4 | $483M | Buy |
2,043,095
+42,554
| +2% | +$9.76M | 2% | 17 |
|
|
2020
Q3 | $544M | Sell |
2,000,541
-21,226
| -1% | -$5.86M | 1.96% | 12 |
|
|
2020
Q2 | $587M | Sell |
2,021,767
-25,507
| -1% | -$6.92M | 2.81% | 9 |
|
|
2020
Q1 | $487M | Sell |
2,047,274
-44,382
| -2% | -$10.2M | 2.72% | 9 |
|
|
2019
Q4 | $458M | Sell |
2,091,656
-231,426
| -10% | -$46.8M | 2.04% | 15 |
|
|
2019
Q3 | $394M | Buy |
2,323,082
+1,582,711
| +214% | +$280M | 1.86% | 21 |
|
|
2019
Q2 | $136M | Sell |
740,371
-11,673
| -2% | -$2.04M | 0.62% | 54 |
|
|
2019
Q1 | $138M | Buy |
752,044
+751,975
| +1,089,819% | +$139M | 0.65% | 56 |
|
|
2018
Q4 | $11K | Buy |
+69
| New | +$12K | ﹤0.01% | 135 |
|
Other funds holding VRTX
Harding Loevner's VRTX Position: Q2 2026 in Review
Harding Loevner reduced its Vertex Pharmaceuticals (VRTX) stake by 100% in Q2 2026, selling an estimated $138M and leaving 1,163 shares worth $578K. The position accounts for 0.01% of the portfolio, ranked #75.
Harding Loevner first reported a position in VRTX in Q4 2018 and has held it in 31 quarters since. The position peaked at $587M in Q2 2020. 1,749 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.
- Harding Loevner held 1,163 shares of Vertex Pharmaceuticals worth $578K as of Q2 2026.
- Harding Loevner sold 312,383 Vertex Pharmaceuticals shares in Q2 2026, an estimated $138M.
- Vertex Pharmaceuticals made up 0.01% of Harding Loevner's portfolio in Q2 2026, its #75 holding.
- Harding Loevner first reported a position in Vertex Pharmaceuticals in Q4 2018 and has held it in 31 quarters since.
- Harding Loevner's Vertex Pharmaceuticals position peaked at $587M in Q2 2020.
- 1,749 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.
Based on Harding Loevner's 13F filing for Q2 2026, filed 14 Aug 2026.